Aura Biosciences’ (AURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a research note published on Wednesday morning,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright also issued estimates for Aura Biosciences’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.99) EPS, FY2026 earnings at ($2.15) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($1.70) EPS and FY2029 earnings at ($1.32) EPS.

Separately, JMP Securities restated a “market outperform” rating and issued a $19.00 target price on shares of Aura Biosciences in a research note on Friday, May 23rd. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Aura Biosciences currently has an average rating of “Buy” and a consensus target price of $22.00.

Aura Biosciences Price Performance

Shares of AURA opened at $6.72 on Wednesday. The firm has a market cap of $417.45 million, a PE ratio of -3.43 and a beta of 0.46. The stock’s fifty day moving average price is $6.62 and its two-hundred day moving average price is $6.53. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. Sell-side analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Institutional Trading of Aura Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new stake in shares of Aura Biosciences during the 4th quarter valued at $50,000. Tower Research Capital LLC TRC raised its stake in shares of Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after purchasing an additional 2,104 shares during the period. GAMMA Investing LLC raised its stake in shares of Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock valued at $57,000 after purchasing an additional 9,573 shares during the period. Invesco Ltd. bought a new stake in shares of Aura Biosciences during the 2nd quarter valued at $76,000. Finally, ProShare Advisors LLC bought a new stake in shares of Aura Biosciences during the 4th quarter valued at $127,000. 96.75% of the stock is currently owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.